Trial Information

Assessment of Response of Patients on Surveillance for Favorable Risk Prostate Cancer to Dutasteride

This analysis is a subset of the data associated with the active surveillance cohort at
Sunnybrook Health Sciences Centre. Approximately 150 subjects within the cohort have
received dutasteride therapy from 6 months to 3 years. All subjects have had serial PSAs at
regular intervals between 3 to 6 months, and all have had a biopsy performed within 1 to 3
years of initiating dutasteride. The prevalence of a secondary rise in PSA > 0.5ng/ml will
be calculated with the impact of dutasteride therapy on the PSA doubling time. This
information will be correlated with baseline PSA value, prostate volume, extent of disease
on initial biopsy and baseline PSA kinetics. PSA kinetics will be also correlated with
Gleason score upgrading on repeat biopsy. The rate of negative biopsies in men on
dutasteride therapy will be compared with a similar group of surveillance subjects not
treated with dutasteride.